Sir Gregory Winter, CBE, FRS, FMedSci, HonFRCP Non-Executive Director & Chairman
Gregory is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge, and a Fellow of Trinity College Cambridge. He has served LMB as a Head of Division, Deputy Director and Acting Director. His scientific career has almost entirely been based in Cambridge where his work included protein sequencing (aminoacyl tRNA synthetases) and nucleic acid sequencing (influenza virus). He later developed technologies for making humanised antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and also for making human antibodies in bacteria (by use of antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market were developed using methods devised by him. He was a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics. Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to Molecular Biology. Sir Greg also chairs the Biosceptre Science Advisory Board.
Gavin Currie Chief Executive Officer
Gavin was appointed CEO of Biosceptre International Ltd in October 2012, having been a Board member since 2009. Prior to taking the CEO role at Biosceptre, Gavin was General Manager of Creata Ventures, a family-held investment fund with a strong biotech focus. Biosceptre was a key investment within that fund.
Gavin previously founded a boutique transaction services company and has significant experience in M&A, particularly integrating businesses post transaction. Gavin has developed a reputation for delivering value by commercialising previously unseen opportunities and has been employed internationally in Australia, New Zealand, England, USA and Hong Kong, with experience in cross-border transactions and investments.
Dr Ron Watts, PhD Non-Executive Director
Ron has worked at senior levels in government and at CEO and Board level across a range of technology-based enterprises.
His management experience covers software and telecommunications industries, and as a consultant he has worked with companies on strategy and fund-raising in biotechnology, utilities, food processing and energy. He co-founded Australia’s largest energy market intermediary, Energy Action and is its chairman.
Ron has served on a number of government and industry oversight bodies, and as Adjunct Research Fellow at UniSA. He has a Bachelor of Science (Honours) from the University of New South Wales and a PhD from Cambridge University.
Michael Lovett Non-Executive Director
Michael is Chairman of MobiLife Pty Ltd – a drug compounding company; owner of Bioption Investments (HK) Ltd – a private investment fund; owner of Ambrosia Trading (Shanghai) Ltd – a manufacturing business; Non Executive Director of KaosKey Pty Ltd – a medical device company; and a Non Executive Director of Dr’s Beck & Stone – a China based veterinary hospital group.
Michael is a qualified psychologist, he founded and was the CEO of one of the UK’s largest social care businesses which after growing organically and through acquisitions he sold to Private Equity. After moving to Hong Kong Michael expanded his entrepreneurial interests by setting up a private investment vehicle through which he invests predominantly in the medical sciences and medical device sector.
Michael is a Fellow of the Royal Society of Arts and of the Institute of Directors.
Andrew Walton-Green Non Executive Director
Andrew joined Biosceptre in December 2014. He is a Chartered Accountant and a member of the Chartered Institute of Taxation. Most recently, Andrew was a founder and CEO of The Car Finance Company, one of the fastest growing companies in Europe over the past 4 years. He is also a part owner of a renewable energy business in the UK, a technology distribution company and a fast growing wholesale pharmaceutical business.
Before this he was the CEO of Gresham Computing plc for 10 years, gaining significant exposure to the banking and financial services sector at a senior level. Andrew spent the first 13 years of his career in practice predominately with Ernst & Young and then Deloitte.
Jon Collins Non Executive Director
Jon joined the board of Biosceptre in December 2014. Jon is the owner and Chairman of The Coco Group, an investment and business expansion consultancy based in Australia, with global connections. Jon moved to Australia in 1987, to rebuild an existing group of businesses for which he led a successful management buy-out from the UK owners in 1993, and became the sole owner in 1997. This business developed into a major manufacturer of specialised pumping equipment with offices in the USA, Indonesia, UK, Middle East and South Africa. The company was sold to an ASX-listed company in November 2010. Jon started his industrials career in 1967, in capital equipment sales and equipment rental, taking posts in the USA and Ireland, and rose through the ranks from junior management to a directorship.
With a keen interest in rugby, Jon has also served as a director of the New South Wales Waratahs (Super 15) and the Australian Rugby Union.
Paul Axon Non Executive Director (Alternate to Jon Collins)
Paul Axon is a qualified Pharmacist and a Chartered Accountant in the UK and Australia, having vast experience in mergers and acquisitions, corporate finance and general management. Previously, Paul was a partner in corporate finance at BDO in the UK and had owned his own mergers and acquisitions practice. More recently, Paul was the CEO of Sykes Pumps, until the sale of the business to National Hire in 2010.
Currently, Paul is the CEO and equity holder of the Coco Group, who invests in and manages a vast array of businesses in Australia and the Middle East, including interests in equipment rental, mining services, retail, biotechnology and resources.